Stelara OK'd for Psoriatic Arthritis
Title: Stelara OK'd for Psoriatic ArthritisCategory: Health NewsCreated: 10/5/2013 11:00:00 AMLast Editorial Review: 10/7/2013 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - October 7, 2013 Category: Dermatology Source Type: news
Stelara OK'd for Psoriatic Arthritis
Stelara, an injectable drug already approved to treat psoriasis, is now also approved to treat psoriatic arthritis. (Source: WebMD Health)
Source: WebMD Health - October 4, 2013 Category: Consumer Health News Source Type: news
FDA OKs Stelara for Psoriatic Arthritis
(MedPage Today) -- The FDA has approved ustekinumab (Stelara) for the treatment of moderate-to-severe psoriatic arthritis in adult patients, drugmaker Janssen Biotech announced Monday. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 25, 2013 Category: Dermatology Source Type: news
Ustekinumab Approved for Psoriatic Arthritis in US, EuropeUstekinumab Approved for Psoriatic Arthritis in US, Europe
Ustekinumab becomes the first and only interleukin 12/23 inhibitor approved for psoriatic arthritis in the United States. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2013 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Stelara® receives CHMP positive opinion
Janssen-Cilag International NV ("Janssen") has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of STELARA® (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 13, 2013 Category: Drugs & Pharmacology Source Type: news
CHMP Says Yes to New Indication for Ustekinumab CHMP Says Yes to New Indication for Ustekinumab
The committee recommends approval of the drug for the treatment of active psoriatic arthritis in adults who fail other therapies. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2013 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Safety of Ustekinumab in Moderate-to-Severe PsoriasisSafety of Ustekinumab in Moderate-to-Severe Psoriasis
This study looked at patients treated for up to five years. The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 16, 2013 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Ustekinumab Leads To Significant Improvements In Psoriatic Arthritis
New PSUMMIT 2* data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA). Anti-TNF naïve and anti-TNF-experienced patients randomised to one of two ustekinumab doses (45mg or 90mg) demonstrated significant and sustained improvements in the signs and symptoms of PsA, with favourable safety profiles... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 14, 2013 Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news
Ustekinumab Efficacy Sustained for Psoriatic ArthritisUstekinumab Efficacy Sustained for Psoriatic Arthritis
Open-label results from PSUMMIT II show that ustekinumab improves signs and symptoms of psoriatic arthritis, functional ability, and psoriasis of the skin at 1 year. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Stelara Succeeds in Psoriatic Arthritis (CME/CE)
MADRID (MedPage Today) -- The monoclonal antibody ustekinumab (Stelara) had sustained benefits through a year of treatment among patients with active psoriatic arthritis, even if they had previously not done well on a tumor necrosis factor inhibitor, a researcher reported here. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 12, 2013 Category: Dermatology Source Type: news
Significant improvements in psoriatic arthritis with ustekinumab
(European League Against Rheumatism) New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2013 Category: Global & Universal Source Type: news
Ustekinumab in Refractory Palmoplantar Pustular PsoriasisUstekinumab in Refractory Palmoplantar Pustular Psoriasis
This case series evaluates the benefit of the biologic agent ustekinumab in severe refractory palmoplantar pustular psoriasis. The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2013 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
